Skip to main content
Fig. 6 | Biomarker Research

Fig. 6

From: KSR2-14–3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma

Fig. 6

KSR2 interacts with 14–3-3ζ and promotes the proliferation of HCC cells through the MAPK pathway. A Protein interaction mass spectrum analyzed by immunoprecipitation in PLC/PRF/5 and MHCC97H cells. Venn diagram shows the intersection of the interacting proteins obtained after KSR2 overexpression in PLC/PRF/5 and MHCC97H cells. B Expression score of proteins interacting with KSR2. C GO and KEGG analysis of the Top 100 genes. D A protein–protein interaction (PPI) network of KSR2 with the hub genes. E Expression score of the hub genes interacting with KSR2. F Interaction between KSR2 and 14–3-3ζ was detected by co-IP in PLC/PRF/5 and MHCC97H cells. G qPCR confirming the transcription level of KSR2 after knocking down 14–3-3ζ as well as the knockdown efficiency of 14–3-3ζ. H Western blot showing the effects of knocking down 14–3-3ζ on phosphorylation in the KSR2 overexpression and control groups. I IF showing the localization of KSR2 and 14–3-3ζ in HCC tissue. J Clonogenic survival of control and KSR2-overexpressing but with 14–3-3ζ-knockdown cells. K Overexpression of KSR2 and knockdown of 14–3-3ζ affects the number of clones formed from PLC/PRF/5 cells. *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page